Associations - EGFR expression

EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval	necitumumab Sensitive: A1 - Approval
EGFR expression EGFR expression	Colorectal Cancer CRC	EGFR expression EGFR expression	Colorectal Cancer CRC	cetuximab Sensitive: A1 - Approval	cetuximab Sensitive: A1 - Approval
EGFR expression EGFR expression	Chordoma Chordoma	EGFR expression EGFR expression	Chordoma Chordoma	lapatinib Sensitive: A2 - Guideline	lapatinib Sensitive: A2 - Guideline
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A2 - Guideline	erlotinib + ramucirumab Sensitive: A2 - Guideline
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: B - Late Trials	erlotinib Sensitive: B - Late Trials
EGFR expression EGFR expression	Colorectal Cancer CRC	EGFR expression EGFR expression	Colorectal Cancer CRC	panitumumab Sensitive: B - Late Trials	panitumumab Sensitive: B - Late Trials
EGFR expression EGFR expression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	EGFR expression EGFR expression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials	ado-trastuzumab emtansine Sensitive: B - Late Trials
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C1 - Off-label	cetuximab Sensitive: C1 - Off-label
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
EGFR expression EGFR expression	Ovarian Cancer Ovarian Cancer	EGFR expression EGFR expression	Ovarian Cancer Ovarian Cancer	gefitinib Resistant: C3 – Early Trials	gefitinib Resistant: C3 – Early Trials
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	sintilimab Sensitive: C3 – Early Trials	sintilimab Sensitive: C3 – Early Trials
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Resistant: C3 – Early Trials	PD-L1 inhibitor Resistant: C3 – Early Trials
EGFR expression EGFR expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	EGFR expression EGFR expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	trastuzumab + erlotinib Sensitive: C3 – Early Trials	trastuzumab + erlotinib Sensitive: C3 – Early Trials
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C3 – Early Trials	osimertinib Sensitive: C3 – Early Trials
EGFR expression EGFR expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR expression EGFR expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
EGFR expression EGFR expression	Lung Adenocarcinoma LUAD	EGFR expression EGFR expression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	anlotinib + APL-502 Sensitive: C3 – Early Trials	anlotinib + APL-502 Sensitive: C3 – Early Trials
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	cetuximab + afatinib Resistant: C3 – Early Trials	cetuximab + afatinib Resistant: C3 – Early Trials
EGFR expression EGFR expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	EGFR expression EGFR expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	lapatinib Sensitive: C3 – Early Trials	lapatinib Sensitive: C3 – Early Trials
EGFR expression EGFR expression	Lung Adenocarcinoma LUAD	EGFR expression EGFR expression	Lung Adenocarcinoma LUAD	afatinib Sensitive: C4 – Case Studies	afatinib Sensitive: C4 – Case Studies
EGFR expression EGFR expression	Glioblastoma GBM	EGFR expression EGFR expression	Glioblastoma GBM	paclitaxel Sensitive: D – Preclinical	paclitaxel Sensitive: D – Preclinical
EGFR expression EGFR expression	Glioblastoma GBM	EGFR expression EGFR expression	Glioblastoma GBM	selumetinib Sensitive: D – Preclinical	selumetinib Sensitive: D – Preclinical
EGFR expression EGFR expression	Glioma Glioma	EGFR expression EGFR expression	Glioma Glioma	gefitinib Sensitive: D – Preclinical	gefitinib Sensitive: D – Preclinical
EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	vandetanib Sensitive: D – Preclinical	vandetanib Sensitive: D – Preclinical
EGFR expression EGFR expression	Pancreatic Cancer Pancreatic Cancer	EGFR expression EGFR expression	Pancreatic Cancer Pancreatic Cancer	afatinib Sensitive: D – Preclinical	afatinib Sensitive: D – Preclinical
EGFR expression EGFR expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	EGFR expression EGFR expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	AFM24 Sensitive: D – Preclinical	AFM24 Sensitive: D – Preclinical